

# **XV. Multiple myeloma & III. Cell therapy workshop**

*on-line version*

**Thursday 12.11.2020**

**9:30 – 9:40**

**R.Hájek / M.Šimíček**

Intro

## **Genomics of monoclonal gammopathies**

**9:45 – 10:00**

**M.Zátopková**

Genomics of minimal residual disease in MM

**10:05 – 10:25**

**D.Žihala**

Genomics in MM extramedullary disease

**10:30 - 11:00 Break**

## **Novel molecular aspects in MM biology and therapy**

**11:00 – 11:20**

**A.Vdovin**

Proteasome inhibitor resistance in MM: *a lesson from immunoglobulin synthesis*

**11:25 – 11:35**

**R.Šnaurová**

Novel factors regulating Ig production in plasma cells

**11:40 – 11:45**

**M.Turi**

Analysis of MyD88 signalosome driving human lymphomas

**12:00 - 13:00 Break**

## **In vivo models and CD38 in MM**

**13:00 – 13:15**

**M.Hrdinka**

Mouse models in hematooncology

**13:20 – 13:35**

**H.Šahinbegović**

Many aspects of CD38 targetability in MM

**13:10 – 13:25**

**T.Jelínek**

Daratumumab in MM extramedullary disease

**13:30 - 14:00 Break**

### **Cell-based therapy section**

**14:00 – 14:15**

**P. Celichowski**

Immunotherapy with universal T cells

**14:20 – 14:35**

**B.Motais**

Allogeneic NK cells for cancer treatment

**14:40 – 14:55**

**Z.Kořístek / I.Demel**

NK cell therapy - results of clinical trials

**15:00 – 15:15**

**T.Ševčíková**

Follow-up ALA genomics project - review and project design

**15:15 – 15:45**

**Open discussion**

**15:45 – 15:50**

**R.Hájek / M.Šimíček**

Concluding remarks